Divi's Laboratories Shares Surge After HSBC Upgrades to 'Buy'

ratories shares climbed nearly 1% to Rs 6,952 on NSE after HSBC upgraded its rating to "buy" and raised the target price by over 50% to Rs 7,900 from Rs 5,200, implying a 12% upside. HSBC projects a 23% CAGR in earnings per share from 2024-25 to 2027-28, driven by tirzepatide and other peptides, with revenue potential of $450 million from peptides and $260 million from contrast media by 2030. For Q4 FY25, Divi's reported a 25.6% YoY net profit increase to Rs 667 crore and a 12.26% YoY revenue rise to Rs 2,536 crore. The stock's 52-week range is Rs 4,395–7,071, with a market cap of Rs 1.84 lakh crore.